CASI Pharmaceuticals analyst ratings
CASI Pharmaceuticals analyst ratings
While ratings are subjective and will change, the latest CASI Pharmaceuticals (CASI) rating was a maintained with a price target of $4.00 to $21.00. The current price CASI Pharmaceuticals (CASI) is trading at is $3.71, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 06/03/2022 | 466.04% | BTIG | $4 → $21 | Maintains | Buy |
| 05/16/2022 | -19.14% | HC Wainwright & Co. | $4 → $3 | Maintains | Buy |
| 05/18/2021 | 7.82% | BTIG | → $4 | Initiates Coverage On | → Buy |
| 05/14/2021 | 7.82% | HC Wainwright & Co. | $3.5 → $4 | Maintains | Buy |
| 04/26/2021 | 2.43% | Mizuho | → $3.8 | Initiates Coverage On | → Buy |
| 10/23/2020 | 34.77% | Oppenheimer | → $5 | Initiates Coverage On | → Outperform |
| 03/24/2020 | -5.66% | HC Wainwright & Co. | $7 → $3.5 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 06/03/2022 | 466.04% | BTIG | 4 美元 → 21 美元 | 維護 | 買 |
| 05/16/2022 | -19.14% | HC Wainwright & Co. | 4 美元 → 3 美元 | 維護 | 買 |
| 05/18/2021 | 7.82% | BTIG | → 4 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 05/14/2021 | 7.82% | HC Wainwright & Co. | 3.5 美元 → 4 美元 | 維護 | 買 |
| 04/26/2021 | 2.43% | 瑞穗市 | → 3.8 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2020 年 10 月 23 日 | 34.77% | 奧本海默 | → 5 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2020 年 3 月 24 日 | -5.66% | HC Wainwright & Co. | 7 美元 → 3.5 美元 | 維護 | 買 |
CASI Pharmaceuticals Questions & Answers
CASI 製藥問題與解答
The latest price target for CASI Pharmaceuticals (NASDAQ: CASI) was reported by BTIG on June 3, 2022. The analyst firm set a price target for $21.00 expecting CASI to rise to within 12 months (a possible 466.04% upside). 2 analyst firms have reported ratings in the last year.
BTIG於2022年6月3日公佈了卡西製藥（納斯達克股票代碼：CASI）的最新目標股價。該分析公司將目標股價定爲21.00美元，預計CASI將在12個月內升至12個月內（可能上漲466.04％）。去年有兩家分析公司公佈了評級。
The latest analyst rating for CASI Pharmaceuticals (NASDAQ: CASI) was provided by BTIG, and CASI Pharmaceuticals maintained their buy rating.
CASI Pharmicals（納斯達克股票代碼：CASI）的最新分析師評級由BTIG提供，CASI Pharmicals維持買入評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CASI Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CASI Pharmaceuticals was filed on June 3, 2022 so you should expect the next rating to be made available sometime around June 3, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與CASI Pharmicals的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。CASI Pharmicals的最新評級是在2022年6月3日發佈的，因此您應該預計下一個評級將在2023年6月3日左右公佈。
While ratings are subjective and will change, the latest CASI Pharmaceuticals (CASI) rating was a maintained with a price target of $4.00 to $21.00. The current price CASI Pharmaceuticals (CASI) is trading at is $3.71, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的CASI Pharmicals（CASI）評級維持不變，目標股價爲4.00美元至21.00美元。CASI Pharmicals（CASI）目前的交易價格爲3.71美元，超出了分析師的預期區間。
